Mylan’s Ethical Meltdown

It has been quite a month for Mylan beginning with its first ethical lapse when it raised the price of the EpiPen by $500 from its 2008 price.  Facing a tidal wave of criticism, Mylan, a week later, pivoted and announced the launch of a generic EpiPen at one-half the price of the branded product, but still three times the 2008 price. Mylan now finds itself alone in a hostile wilderness…

A Perfect Storm – Generics, Labeling, Price and Risk

For those in the generic drug industry, a storm has been brewing for some time now; a storm that has been largely invisible to the rest of the public. At its heart is the rising cost of pharmaceutical products and, in particular, generic products.  Now that almost 80% of the prescriptions in the U.S. are filled with generics and generic drug prices are on the rise despite demonstrated cost savings (see graph below),…

A bad day for the good guys

Just when we thought it couldn’t get any worse, the first day of fall has turned out to be one of the worst for the ethical good guys.  As though the VW scandal wasn’t bad enough, the pharmaceutical industry has its own VW scandal in the form of Marc Shkreli and Turing Pharmaceuticals, who are simply raising the price of Daraprim, a staple to treat toxoplasmosis, by a reported 5000%.…

Sunshine hits the UK National Health Service

As we’ve been noting for some time now, transparency efforts in the life sciences industry are here to stay.   Within the last 48 hours, the UK has stepped up the game by announcing new rules for National Health Service (NHS) hospitals and General Practitioner groups (Policy & Medicine, Daily Mail).   The so-called “Sunshine rule” will be introduced next year, and will require NHS organizations to maintain a list…